Evidence Hub

Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective

Xiaoran Sun

American Journal of Translational Research, 2025

1 citation

Abstract

Objective: To evaluate the eradication effect of dual therapy based on rabeprazole or vonoprazan for Helicobacter pylori (Hp) infection.Methods: Data from 300 Hp-positive patients were retrospectively analyzed.Patients who received rabeprazole and amoxicillin were assigned to the rabeprazole group, those who received vonoprazan and amoxicillin were placed in the vonoprazan group, and those who underwent conventional quadruple therapy (omeprazole + amoxicillin + clarithromycin + bismuth potassium citrate) were included in the control group.Clinical medical records, including baseline characteristics, symptom manifestations, examination results, treatment regimens, and treatment costs, were collected.The Hp eradication rate, symptom relief, levels of inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP)), incidence of adverse reactions, treatment compliance, and cost-effectiveness ratio (C/E) were compared among the three groups.Results: In both per-protocol (PP) and intention-to-treat (ITT) analyses, no statistically significant differences were observed in eradication rates among the three groups (P>0.05).Symptom relief was more pronounced at 44 days of treatment compared to 14 days across all groups (P<0.05).At both 14 and 44 days, significant differences were found in the relief of abdominal distension (14 days: Z=20.644,P<0.001; 44 days: Z=11.577,P=0.003) and belching (14 days: Z=23.234,P<0.001; 44 days:…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free